This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Drug Delivery Remove Pharma Companies Remove Reagent Related Topics
In-Vivo In-Vitro Genetic Disease Doctors Gene Editing Life Science DNA Gene Therapy Clinical Research Medicine More Related Topics >
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. This project still acts as a robust proof-of-concept for the potential of our technology in diagnostics and as assay reagents. Does the use of automation allow the company to maintain lower staff levels?

Antibody 52
Antibody Gene Therapy Gene In-Vitro 52
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.

Scientist 52
Scientist In-Vitro Research Life Science 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024